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Abstract
Coagulopathy and angiogenesis are among the most
consistent host responses associated with cancer.
These two respective processes, hitherto viewed as
distinct, may in fact be functionally inseparable as blood
coagulation and fibrinolysis, in their own right, influ-
ence tumor angiogenesis and thereby contribute to
malignant growth. In addition, tumor angiogenesis
appears to be controlled through both standard and
non-standard functions of such elements of the hemo-
static system as tissue factor, thrombin, fibrin, plasmi-
nogen activators, plasminogen, and platelets. ‘‘Cryptic’’
domains can be released from hemostatic proteins
through proteolytic cleavage, and act systemically as
angiogenesis inhibitors (e.g., angiostatin, antiangio-
genic antithrombin III aaATIII ). Various components of
the hemostatic system either promote or inhibit angio-
genesis and likely act by changing the net angiogenic
balance. However, their complex influences are far from
being fully understood. Targeted pharmacological and/
or genetic inhibition of pro-angiogenic activities of the
hemostatic system and exploitation of endogenous
angiogenesis inhibitors of the angiostatin and aaATIII
variety are under study as prospective anti -cancer
treatments. Neoplasia (2001) 3, 371–384.
Hemostasis, Angiogenesis, and Tumor Progression
The hemostatic system is anatomically and functionally
inseparable from the vasculature. It is therefore somewhat
ironic that in the context of cancer, these respective host
elements have, until recently, been studied as virtually
independent entities. This article is intended to illustrate the
ongoing revision of this historical view and to summarize the
therapeutic potential of targeting elements of the hemostatic
system as a strategy to inhibit tumor angiogenesis.
Close association between malignant disorders and
various perturbations in blood coagulation has been recog-
nized for over 130 years [1 ]. Coagulation dysfunctions of
different nature and magnitude, ranging from subtle labo-
ratory abnormalities to overt thromboembolism, thrombo-
phlebitis, and disseminated intravascular coagulation, are
routinely found in cancer patients [2–8]. Up to 50% of all
patients with malignant disease and up to 90% of those with
metastatic lesions demonstrate abnormalities in hemostatic
parameters [5 ]. In this regard, pancreatic cancer, breast
cancer, and particularly acute promyelocytic leukemia are
the best -described examples [7,9]. However, cancer-
related hemostatic complications are usually heterogenous
in nature and their pathogenesis is often poorly understood.
This is why they are often collectively referred to as ‘‘cancer
coagulopathy’’ or ‘‘paraneoplastic syndrome’’ [2 ], as their
manifestations are found at both the systemic level (dere-
gulation of blood coagulation) and locally at the tumor site
(crosslinked extravascular fibrin and fibrinogen) [10–13].
There are ample data suggesting that these respective
changes are not merely an epiphenomenon of the disease,
but rather represent an integral part of the pathobiology of
tumor growth and dissemination [2,14–16]. In this regard,
the interrelationship between cancer coagulopathy and the
onset of tumor angiogenesis is of particular interest.
It is widely accepted that most primary tumors and
metastatic lesions cannot grow beyond 2 to 3 mm in size in
the absence of vascularization [17]. Regardless of whether
the latter is secured by occasional ‘‘cooption’’ of preexisting
capillaries [18] or by active recruitment of their new
extensions (angiogenesis ) [17,19,20], tumor-associated
vasculature is essential not only to ensure continued
metabolite and oxygen exchange but also as a source of
important ‘‘paracrine stimulation’’ [21] through endothelial
cell–derived extracellular matrix (ECM) [22], proteases [23]
and cytokines, regulating tumor cell growth [24], survival
[25], invasion [26], and metastasis [27].
It is now thought that the onset of tumor neovasculariza-
tion ( ‘‘angiogenic switch’’ ) results from a shift in balance
between angiogenesis stimulators and inhibitors released by
both tumor parenchyma and ‘‘activated’’ host stromal cells
[28–32]. Among the latter, stromal fibroblasts [33,34], mast
cells [35], resident macrophages [36], blood-borne mono-
nuclear leukocytes [15,37,38], and platelets [39,40] are
considered the main sources of angiogenesis regulators.
Operationally, pro-angiogenic conditions may be trig-
gered by a gain-of - function and/or a loss-of - function event
[28,32,41]. In the former case, angiogenesis stimulators
such as vascular endothelial growth factor (VEGF), mem-
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bers of the fibroblast growth factor family (e.g., bFGF,
aFGF), hepatocyte growth factor (HGF), or other similarly
acting entities are induced or upregulated in the tumor
microenvironment, evoking responses of normally quies-
cent capillary endothelial cells [42,43]. Conversely, such
pro-angiogenic state may result from downregulation of
constitutively expressed angiogenesis inhibitors acting
either locally (e.g., thrombospondin-1 and -2 (TSP-1, -
2), maspin, brain-specific angiogenesis inhibitor 1 (BAI1),
pigment epithelium–derived factor (PEDF), interferons ,
, and , Meth-1, -2) [32,44–47] or systemically
(agiostatin, endostatin, vasostatin, aaATIII ) [48–51]. The
combined, cumulative impact of those various types of
influences is believed to be responsible for initiation and
maintenance of tumor angiogenesis and resulting escape
from a dormant avascular state [28].
In the context of cancer, the imbalance between angio-
genesis stimulators and inhibitors can be ultimately traced
to direct or indirect influences exerted by genetic events
underlying the disease progression [32,52,53]. Thus, loss-
of - function mutations in several tumor suppressor genes
(e.g., p53 ) can trigger changes in expression of both
angiogenesis inhibitors (e.g., TSP-1, BAI-1) [32] and
stimulators (e.g., VEGF) [54–56]. Likewise, gain-of -
function genetic events, such as activation of dominant
transforming oncogenes in tumor cells (e.g., ras, myc,
EGFR, or HER-2), affect expression of multiple molecular
effectors of angiogenesis [41]. In both cases, the impact of
genetic lesions can be greatly amplified by epigenetic
influences such as hypoxia [57–60], cell–cell contact
[53,61], paracrine growth factors, and inflammatory cyto-
kines present in the tumor microenvironment [53,62].
Factors produced by transformed cells can also attract,
activate, and induce angiogenic phenotype in host stromal
cells [35], thereby promoting the process in an ‘‘indirect
manner.’’ It is interesting that in a similar fashion,
consequences of cellular transformation may also partic-
ipate in deregulation of the hemostatic system with
resulting modulation of vascular responses [63]. In this
regard, Rak and Klement [63] have recently proposed that
transforming genetic changes can play a causative role in
‘‘cancer coagulopathy’’ by changing the expression of
tissue factor (TF), proteases, VEGF, and other mediators.
Such genetic influence would likely exert at least an
‘‘indirect’’ effect on tumor angiogenesis. While many
scenarios can be envisaged how such genetically driven
tumor angiogenesis–hemostasis crosstalk can be realized,
it may be helpful to begin by considering some of the
relevant consequences of the commonly observed upregu-
lation of VEGF in tumors, an event for which a genetic
cause is relatively well defined [41].
In 1979, Dvorak et al. [64] suggested that tumor
neovascularization can be explained by apparent capillary
hyperpermeability at the tumor site and resulting leakage of
fibrinogen into extravascular spaces followed by formation of
the pro-angiogenic fibrin matrix. He argued that it is the
tumor vascular permeability factor (VPF), rather than then
hypothetical tumor angiogenesis factor (TAF) [17,65], that
causes formation of the intratumoral capillary network [64].
In 1983, VPF was biochemically identified [66] and in 1989
cloned and found to be identical with the newly discovered
endothelial mitogen named VEGF [67,68]. VEGF/VPF
(VEGF-A) is now known to be the central endothelial
cell–specific growth factor, angiogenesis inducer, survival
factor, and permeability regulator, the expression of which is
upregulated in the vast majority of solid tumors and
leukemias [69]. The corresponding gene (VEGF-A ) con-
tains a classical hypoxia- responsive element in its 50
untranslated region and is normally under physiological
control of the hypoxia- inducible factor 1 (HIF-1), a tran-
scription factor regulated by an oxygen-sensing cellular
mechanism [70]. However, it is now believed that upregu-
lation of VEGF in many tumor cells is not solely a result of
hypoxia, but rather is linked to genetic changes associated
with malignant transformation [41]. Some of these changes
(expression of activated src oncogene, loss of p53 tumor
suppressor gene) act by mimicking the intracellular signals
normally induced by hypoxic conditions [70], while others
(e.g., mutational activation of ras oncogenes) can amplify
the effect of hypoxia [57,62,70] or act in a constitutive
manner to stimulate VEGF expression [71]. Once released
from tumor cells, VEGF acts specifically on at least five types
of endothelial cell receptors, namely, VEGFR-1/ flt -1,
VEGFR-2/ flk-1/KDR, VEGFR-3/ flt -4, and non-kinase
co-receptors neuropilins-1 and 2 (NP-1, 2) [68,72–74].
The vascular permeability– inducing effects of VEGF/VPF,
which are thought to promote fibrinogen extravasation and
extravascular clotting, are known to be regulated by a
concerted action of VEGFR-2, c-src kinase, focal adhesion
kinase, and v5 integrin [75,76]. While the case of VEGF is
very instructive, it merely exemplifies the more extensive and
complex tripartite interactions that, in different pathological
contexts, may occur among tumor parenchyma, micro-
vasculature, and the hemostatic system.
Angiogenic Activities of the Coagulation System
Several constituents of both intrinsic and extrinsic coagu-
lation cascades have been found to possess overt or cryptic
angiogenesis- regulating properties [40]. They include, e.g.,
angiogenesis inhibitory activity expressed by kininostatin,
i.e., domain 5 of the high-molecular -weight kininogen (HK)
[77], elastase/ thrombin–cleaved fragment of antithrombin
III [49 ], and possibly factor XIII [78 ]. Activities that may
stimulate or modulate tumor angiogenesis are linked even
more strongly with such key regulators of coagulation as TF,
thrombin, and fibrinogen/ fibrin, an issue which deserves a
more thorough discussion.
Tissue Factor
TF is the principal initiator of the extrinsic pathway of
coagulation traditionally recognized to play an important role
in ‘‘cancer coagulopathy’’ [79,80]. Increased expression of
TF has been observed in many tumor types, including small
cell carcinoma, bronchoalveolar carcinoma and large cell
carcinomaof the lung, colon adenocarcinoma, head and neck
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cancer, malignant gliomas, bladder cancer, and prostate
cancer [10,81–85]. Tumor cells express TF constitutively
[80,81] and possibly trigger production of TF by adjacent host
cells, including monocytes and endothelial cells [86].
The functional linkage between TF and angiogenesis has
been implicated by a number of studies, which invoke
existence of several possible complementary mechanisms
of action, such as: 1) generation of pericellular thrombin and
pro-angiogenic thrombin signaling; 2) extravascular coagu-
lation and formation of pro-angiogenic fibrin matrix; and 3)
changes in expression of angiogenic growth factors by
autonomous TF-mediated intracellular signals [85,87–93]
(Figure 1 ).
Studies involving enforced TF downregulation provide
compelling evidence for the causative role of this trans-
membrane receptor protein in developmental and patholo-
gical blood vessel formation. Thus, mice harboring the
homozygous TF null mutation die in utero with /of apparent
abnormalities in their yolk sack vasculature [94,95]. Expres-
sion of the antisense TF mRNA in Meth-A sarcoma led to
decreased transcription of the VEGF gene, increase in
expression of TSP-1, and decline in tumor growth and
vascularity [87]. This apparent interrelationship between
expression of TF and VEGF is of particular interest because
co- localization of these proteins has been documented in
several instances, such as human melanoma cells grown as
xenografts in immunodeficient mice, human breast cancer,
human glioma, and human adenocarcinoma of the lung
[83,88,96].
The expression of both TF [97,98] and VEGF [99–101] is
controlled by hypoxia. Pentoxifylline treatment downregu-
lates TF expression by monocytes and endothelial cells, and
inhibits hypoxia- induced synthesis of both TF and VEGF by
three differentmalignant cell lines [86]. However, while under
low oxygen conditions, VEGF promoter responds mainly to
HIF-1– induced stimulation [70,102]; TF expression is
increased by a mechanism independent of HIF-1 activity,
as it readily occurs in the absence of the  -subunit of HIF-1
[103]. Experiments withmice homozygous for a null mutation
of the early growth response (Egr-1) gene indicated that this
transcription factor is responsible for upregulation of TF in
hypoxic lung tissue [97,98]. Interestingly, Egr-1 also appears
to be responsible for VEGF- and TNF -dependent upregu-
lation of TF by endothelial cells [104]. TF is considered to be
an early response gene, the expression of which is regulated
by serum, growth factors, and cytokines [105].
Structurally, TF gene product is composed of three
functionally distinct domains: namely, the extracellular —
i.e., the factor VIIa — binding region, the transmembrane
domain, and the short cytoplasmatic tail [106]. The relative
contribution of these submolecular regions to VEGF upre-
gulation and angiogenesis has been recently a subject of
intensive experimental exploration, but also of some debate.
Thus, re-expression of the extracellular domain alone was
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Figure 1. The ‘‘vicious circle’’ of coagulation and angiogenesis in cancer [ 63 ]. Tumor cells are thought to acquire angiogenic properties under the influence of
transforming changes, i.e., expression of oncogenes and /or tumor suppressor genes (TSG). Resulting onset of VEGF production, along with imbalance in
expression of other angiogenesis stimulators and inhibitors, triggers several endothelial cell responses, such as new blood vessel formation, expression of tissue
factor (TF ), and vascular permeability. This complex reaction allows extensive contact ( and activation ) of coagulation factors (VII, X, II ) in plasma with pro -
coagulant extravascular environment ( tumor parenchyma, stroma, ECM) and TF -positive tumor endothelium. TF - and PARs -mediated intracellular signals
induce further increase in expression of angiogenic factors ( e.g., VEGF) by tumor cells. TF signaling also sensitizes endothelial cells to further VEGF stimulation
( see text for details ).
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shown to rescue the TF  / phenotype in mice and prevent
both embryonal lethality and vascular defects [107]. This
may indirectly imply that, if VEGF is the main mediator of the
TF-dependent prenatal angiogenesis, the extracellular
domain of TF may be both necessary and sufficient to
control VEGF levels. Contrary to this result, Abe et al. [92]
demonstrated that transfection of human melanoma cells
with the cDNA encoding TF cytoplasmic domain alone
resulted in elevated VEGF expression. Furthermore, the
cytoplasmatic domain of TF has been recently implicated in
triggering protein kinase C–dependent signalling, a mech-
anism known to mediate VEGF upregulation by a variety of
stimuli [108–110]. Although intriguing in itself, this postu-
lated exclusive role of the cytoplasmatic domain in pro-
angiogenic, TF-dependent cellular signalling is probably an
exception rather than the rule, if the following observations
are taken collectively: 1) aforementioned ‘‘rescue’’ of the
TF / phenotype in mice by expression of the extracellular
TF domain; 2) dependence of TF- induced Ca2+ oscillations
and changes in gene expression in several cell types upon
binding of fVIIa ( to the extracellular domain of TF)
[109,111–113]; 3) activation of MAPK pathway, a major
inducer of VEGF expression [53,114], by fVIIa /TF inter-
actions [115,116]; 4) fVIIa /TF complex–dependent activa-
tion of phosphatidyl inositol 30 -OH kinase (PI3K) and
members of src family of kinases, both involved in angio-
genesis [117]; and 5) TF-mediated VEGF upregulation in
human fibroblasts driven by activation of factor VII–
associated procoagulant activity and resulting generation of
factor Xa and thrombin [93,118].
The catalytic activity of the TF/VIIa complex triggers
activation of factor X and thrombin, both of which can
change expression of various genes ( likely including
angiogenesis regulators), notably through activation of
so-called protease-activated receptors (PARs) on the cell
surface [107]. This effect can be tamed by the action of
the TF pathway inhibitor (TFPI), synthesized by vascular
endothelial cells and macrophages [119]. TF can also form
a quaternary complex with factor VIIa, factor Xa ( fXa), and
cell -bound TFPI — an interaction which results in cellular
transport of TF to small plasmalemmal vesicles (caveo-
lae), downregulation of its proteolytic activity, and placing it
in the proximity of such elements of intracellular signaling
as G-protein–coupled receptors, non-receptor tyrosine
kinases, and the plasma membrane Ca2+ pumps [8,120–
122]. The consequences of these latter events for angio-
genesis remain to be elucidated.
Endothelial cells stimulated with VEGF upregulate the
expression of TF on their surfaces [104,106,123] — an
event likely to induce procoagulant conditions within the
tumor microvasculature. This is consistent with the obser-
vation that TF is often upregulated on endothelial cells
associated with VEGF-positive tumors [88]. It is tempting to
speculate that the mutual interrelationship between VEGF
and TF expression may constitute a centerpiece of the pro-
angiogenic feedback loop in tumors (compare Figure 1 ).
However, VEGF can also stimulate expression of the
elements of the fibrinolytic cascade, including: plasminogen
activators (PAs; u-PA and t-PA), urokinase receptor (u-
PAR) [124], and plasminogen activator inhibitor 1 (PAI-1)
[125]. Collectively, these are not merely uncontrolled
changes in proteolytic activities of the host hemostatic and
fibrinolytic systems, but rather manifestations of a new
equilibrium that favors tumor vascularization invasion and
metastasis [20,106,126].
Thrombin
Activation of TF-dependent blood coagulation leads to
generation of thrombin, the presence of which has been
detected in several tumor types (small cell lung cancer, renal
cancer, malignant melanoma, ovarian cancer, laryngeal
cancer, and gastric cancer [10–12,127–130]). Thrombin
per se is believed to contribute to cancer progression
[131,132] through increase in tumor cell adhesiveness,
metastatic potential, and tumor cell– induced platelet aggre-
gation [131]. Thrombin increases TF synthesis in different
cells and thus facilitates activation of blood coagulation in a
self -perpetuating fashion [86]. However, by activating
tissue- type plasminogen-activator inhibitor -1 (PAI-1) and
thrombin-activatable fibrinolysis inhibitor (TAFI) thrombin
also inhibits fibrinolysis [133,134]. Thrombin is pro-migra-
tory [135] and mitogenic for tumor cells, but is also known to
amplify the effects of other mitogens [136,137].
Thrombin is a potent inducer of various processes
involved in angiogenesis (Figure 2 ) [96,138–144]. For
example, its action can induce vascular permeability [133]
via a VE–cadherin and protein–tyrosine phosphatase
SHP2-dependent mechanism [145]. Using the chick chorion
allantoic membrane (CAM) assay, Maragoudakis and
Tsopanoglou [141] and Tsopanoglou et al. [143] demon-
strated that thrombin directly promotes angiogenesis in vivo.
This was executed by a proteolytic mechanism independent
of fibrin formation because both  - thrombin (containing both
the catalytic site and the anionic exosite) and  - thrombin
(catalytically active but lacking the anion-binding exosite
required for clotting activity ) were active in this model [143].
It is not clear whether the same activity is involved in
spontaneous tubule formation by thrombin- treated endothe-
lial cells cultured in Matrigel, an effect dependent on PKC
activity [146]. Furthermore, thrombin was shown to be
directly mitogenic for endothelial cells [147–149] owing to
both proteolytic ( i.e., thrombin receptor–dependent) and
non-proteolytic (via B loop of the  - thrombin chain) signal-
ling pathways [149].
Thrombin exerts an indirect pro-angiogenic effect by
upregulating VEGF expression in fibroblasts [118], as well
as by increasing levels of VEGF receptors on vascular
endothelium [142]. Both VEGFR-1/ flt -1 and VEGFR-2/
KDR/flk -1 were shown to be upregulated in thrombin-
treated HUVEC cells, through a PKC- and MAPK-depend-
ent mechanism [142]. Thrombin has also been reported to
increase the release of VEGF from platelets [150], expres-
sion of pro-angiogenic bFGF by endothelial cells [148], and
release of bFGF from the ECM stores [151].
In endothelial cell cultures, thrombin causes release of
tissue- type plasminogen activator ( t -PA), plasminogen
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activator inhibitor -1 (PAI-1) [152], and activation of
progelatinase A (MMP-2) [153]. It has also been proposed
that thrombin may affect angiogenesis by promoting degra-
dation of the angiogenesis inhibitor TSP-1 [154].
While active thrombin is, for the most part, believed to be
pro-angiogenic, cryptic angiogenesis inhibitory domains do
exist within various domains of prothrombin [40]. Thus,
prothrombin kringle-2 domain ( fragment 2) was shown to
inhibit angiogenesis in the CAM assay [155]. Likewise,
human prothrombin fragment 1+2 was documented to inhibit
bFGF- induced bovine capillary endothelial cell growth and
angiogenesis in the CAM [156].
In the presence of heparin, antithrombin III (AT- III )
inhibits proteolytic action of 60th, thrombin and activated
factor X ( fXa) in plasma. Thrombin and neutrophil elastase
can cleave the thrombin-binding site of AT- III, thereby
generating the anti -angiogenic form of AT- III (aaAT- III ),
which inhibits bFGF- and VEGF- induced endothelial cell
proliferation in vitro and in vivo [49].
Fibrinogen/Fibrin
One of the most important consequences of thrombin
activation is the cleavage of plasma fibrinogen to fibrin [7 ].
Shortened half - life of the plasma fibrinogen and its
increased turnover is often observed in cancer patients
[7,157]. Tumors are frequently surrounded by fibrin(ogen)
matrix also present throughout the tumor stroma (both fibrin I
and II ) [7,10–14,90,96,127–129,158]. This observation, in
conjunction with the extravascular presence of prothrombin
fragment 1+2, constitutes the evidence for activation of the
extravascular coagulation in the tumor microenvironment
[7,13].
Crosslinked fibrin is believed to provide a provisional
matrix that promotes angiogenesis [7,96,158,159] by
supporting endothelial cell adhesion, migration, and
survival [158]. Fibrinogen interacts directly with integrin
v3 [160], an effect which likely provides endothelial cells
with survival signals [161] and is mediated through 572–
574 region of the human fibrinogen chain [162]. Also,
factor XIII, which participates in fibrin crosslinking, can
serve as a ligand for this anti -apoptotic integrin [78].
Stabilization and pro-angiogenic action of bFGF, and
possibly other soluble growth factors, may be promoted by
binding to fibrinogen and fibrin [163–166]. In vitro, fibrin
induces expression of TF by HUVECs [167], expression
of pro-angiogenic chemokine IL-8 in calf pulmonary artery
endothelial cells [159], and expression of PAs and TSP-1
in corneal endothelial cells [167]. Likewise, fibrin degra-
dation products — mainly fragment E — may promote
angiogenesis [168]. It has been shown that fibrinopeptide
B cleavage and exposure of the 15–42 region of the
fibrin molecule by thrombin are necessary for various
biological effects of fibrin such as stimulation of cellular
mitogenesis ( in both HUVECs and human skin fibroblasts)
[169] and endothelial cell spreading [170]. However, it is






































Figure 2. Modulation of angiogenesis by thrombin. Several facets of the angiogenic reaction can be influenced by thrombin in a direct or indirect manner, e.g., by
formation of provisional fibrin matrix ( see text ). Proteolysis of prothrombin and antithrombin III gives rise to angiogenesis inhibitors ( fragments 1 and 1.2, aaATIII,
respectively ). Thrombin - activated platelets release a number actual or potential angiogenesis effectors, including VEGF, PF4, TGF and -, or FGF. Various direct
effects of thrombin on endothelial cells and other cell types that could be involved in the angiogenic process are likely mediated by signals generated from PARs
(PAR-1, PAR -3, PAR-4 ) [ 247 ].
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growth of B16 and LLC tumors after subcutaneous
injection was found to be uninhibited, which may suggest
that all the various functions ascribed to fibrin during tumor
angiogenesis could be redundant [16].
Components of the Fibrinolysis System as Regulators
of Tumor Angiogenesis
Numerous studies have demonstrated enhanced activity of
u-PA in breast, gastric, colon, lung, prostate, and ovarian
cancer, as well as in malignant melanoma and brain
tumors, mostly in association with high grade, clinical
malignancy, and poor prognosis [171–176]. High expres-
sion of t -PA in highly malignant gliomas and breast
cancers often correlates with unfavorable prognosis as
well [177,178]. Paradoxically, elevated PAI-1 also indi-
cates poor prognosis in several types of cancers
[171,176,177], a notion suggesting that change in balance,
rather than utter deregulation and exuberance of the
pericellular proteolysis, is compatible with aggressive tumor
growth and angiogenesis [126].
Proangiogenic growth factors, such as VEGF and bFGF,
are known to increase the expression of PAs, their receptors
(e.g., u-PAR), and PAI-1 by endothelial cells [124,125,
179–181]. VEGF and bFGF synergize in stimulating both
angiogenesis [182,183] and expression of u-PA and its
receptor, u-PAR, in bovine adrenal cortex-derived micro-
vascular endothelial cells [184]. These results are consistent
with co-expression of VEGF and tPA transcripts [185] and
co- localization of t -PA, u-PA, PAI-1, and VEGF in rat
gliomas [186]. Moreover, co-expression of VEGF and u-PA
was found in human colorectal cancer [187].
The ability of endothelial cells to express fibrinolytic
activity is largely attributed to plasminogen and PAs: t -PA
and u-PA. PAs convert a zymogen–plasminogen to
plasmin, an enzyme capable of degrading ECM both directly
and indirectly (e.g., through the activation of latent matrix
metalloproteinases) [152,188]. Regulation of u-PA activity
involves binding to the cell surface receptor (u-PAR) [124].
The single-chain proenzyme u-PA (sc-u-PA) can be
activated more efficiently in the context of the u-PAR. Active
two-chain u-PA is quickly inhibited by PAI-1. The u-PA/
PAI-1 complex is internalized together with u-PAR and
degraded in lysosomes, after which u-PAR is recycled to the
cell surface (see Refs. [189,190] for review). The role of u-
PA/u-PAR system in tumor progression is supported by the
observation that expression of u-PAR is localized to the
leading front of migrating monocytes and invading tumor
cells [124] and that tumor growth and metastasis can be
blocked by anti–u-PA antibodies [191].
Plasmin and PAs have been implicated in angiogenesis -
promoting phenomenon of ‘‘pericellular fibrinolysis’’ [192].
This process, which facilitates endothelial cells invasion into
the fibrin matrix, can be antagonized by plasmin inhibitors,
2-antiplasmin and 2-macroglobulin [192]. Recent study
suggests, however, that PA/plasminogen system is not
essential for endothelial cell penetration into fibrin gels
because such function could be performed by the membrane
type-1 matrix metalloproteinase [193]. Again, it should be
born in mind that both inhibition of the PA/Plg /MMP-
dependent proteolysis and its supraoptimal stimulation ( in
PAI-1 deficiency) are incompatible with effective angio-
genesis [106,126,194].
PA system acts in a complex and pleiotropic fashion so
that it can simultaneously influence, in many ways, endo-
thelial cell adhesion, proteolysis, and signaling (Figure 3 ).
Cell surface u-PAR binds to vitronectin in a PAI-1 inhibitable
manner — an interaction which could clearly promote cell
adhesion and angiogenesis [195]. Moreover, domain 2/3 of
u-PAR expressed on endothelial cells serves as a receptor
for high-molecular -weight kininogen (HK) and this binding
is, in turn, inhibited by interaction with vitronectin [196].
Formation of the HK/kallikrein /u-PAR complex can further
promote fibrinolytic activity and possibly angiogenic com-
petence of endothelial cells [196]. This action can be
antagonized by domain 5 of HK (kininostatin ), which is
known to downregulate endothelial cell proliferation and
migration and thereby inhibit angiogenesis [77]. In a recent
study, two-chain form of HK (HKa), HK domain 6, or
corresponding peptides, but not the intact HK, were shown to
directly bind to and inhibit endothelial cell proliferation,
survival, and angiogenesis in a manner independent of u-
PAR or vitronectin binding [197]. The latter effects should
not be viewed in isolation from the proangiogenic effects
exerted by the entire kinin system. Thus, release of
bradykinin fromHK and enforced overexpression of kallikrein
were both found to be pro-angiogenic under certain
conditions [198–200]. Moreover, interaction between HK
and sc-u-PA with or without factor XII contribution may lead
to plasmin generation on endothelial cell surfaces [201]
and further barrage of complex proteolytic influences on
the progress of angiogenesis. Finally, binding of u-PA to
its receptor triggers intracellular signals [202], which
could modulate angiogenesis in a proteolysis -dependent
or - independent manner [189].
Another activity associated with the PA system, which is
relevant to angiogenesis regulation, is related to the
proteolytic processing of soluble growth factors and cyto-
kines. For example, u-PA can activate pro-HGF, while
plasmin cleaves bFGF, activates latent TGF ( transforming
growth factor  ) [203,204], and can liberate the membrane-
bound isoforms of VEGF (VEGF189) [68]. HGF is known to
possess intrinsic pro-angiogenic properties, but also the
ability to stimulate VEGF production [205,206], and to
promote motility and cellular invasiveness. TGF, while
growth- inhibitory for endothelial cells in vitro, is thought to
promote angiogenesis in vivo by a variety of mechanisms,
such as regulation of ECM formation and proteolysis [171],
participation in blood vessel maturation [20,207,208],
stimulation of VEGF release [209], and inhibition of
angiostatin generation [210].
Discovery of angiostatin is one of the most spectacular
events that illustrate the link between the PA system and
regulation of angiogenesis [211]. Angiostatin, a 38-kDa
cleavage product of mature plasminogen, made up of the
first four of the five highly homologous kringle domains, has
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been detected in tumor-bearing mice as a systemically
acting, circulating angiogenesis inhibitor [211]. At least two
sources of proteases, i.e., matrix metalloelastases (MME)
released from tumor- infiltrating macrophages and serine
proteases produced directly by tumor cells, catalyze plasmi-
nogen conversion to angiostatin or its isoforms [212].
Several such isoforms have been identified. For example,
the 52-kDa isoform of angiostatin containing kringles 1
through 4 and a portion of kringle 5 — so-called ‘‘angiostatin
4.5’’ (apparently generated by plasmin) — was detected in
brain tumors and in malignant ovarian ascites [213]. Another
55-kDa angiogenesis inhibitor was obtained by digestion of
plasminogen with urokinase-activated plasmin, and con-
tains intact kringles 1–4 and most of the kringle 5 (denoted
as K1–5) [214]. In this case, the endothelial cell–specific
inhibitory effect appears to be 50- fold more potent than that
of angiostatin [214]. Also kringle 5 of plasminogen, in itself,
exerts a negative effect on angiogenesis [212]. Recently, a
recombinant protein composed of kringles 1–3 (rPK1–3)
has been reported to inhibit growth of human glioma
xenografts in nude mice [215]. Several studies confirmed
the anti -angiogenic effect of angiostatin or its derivatives in
various systems [216], albeit to a different degree and with
various modifications of the drug delivery. Also, gene therapy
approaches utilizing liposomes complexed to plasmids
encoding angiostatin were found to be effective against
breast cancer in nude mice [217]. Interestingly, radiation
therapy combined with angiostatin treatment can, in some
cases, act synergistically to inhibit expansion of the tumor
vasculature [218].
The molecular mechanism, by which angiostatin inhibits
angiogenesis, remains unclear. In this regard, it is known that
angiostatin binds to the  / -subunits of the ATP synthase
on the surface of endothelial cells, potentially inducing H+
cytoplasmic influx and cytolysis [219]. Furthermore, angios-
tatin may inhibit endothelial cell invasion via complex
formation with t -PA and resulting blockade of the PA/
plasminogen system [220]. In this context, it is thought-
provoking that another inhibitor of angiogenesis, endostatin,
apparently acts through an opposite mechanism, i.e., by
stimulation of plasmin generation and removal of proangio-
genic fibrin matrix [221]. Clearly, further studies are
warranted to elucidate and predict the net effect of the
various fibrinolytic and procoagulant proteases implicated in
angiogenesis.
The Role of Platelets in Tumor Angiogenesis
Analysis of platelets in cancer patients often reveals
quantitative and qualitative abnormalities [39,222,223].
Among those, thrombocytosis; increased, reduced, or
spontaneous aggregation; impaired adhesion; and hyper-
sensitivity to different agonists are the most frequently
cited examples [39,223]. Various types of tumor cells
can activate platelets in vitro by virtue of direct contact,

























Figure 3. Pro - and anti - angiogenic activities encoded within the fibrinolytic system. Amultitude of effects on angiogenesis has been attributed to various effectors of
fibrinolysis. Additional detailed studies are warranted on some of the more recently uncovered modulators of this system, e.g., TAFI [ 248 ] or endostatin [ 221 ]. The
view emerging from ‘‘gene knockout’’ studies is that both excessive activation (PAI -1 deficiency ) as well as excessive inhibition of fibrinolysis (PA deficiency ) are
incompatible with effective angiogenic response [20 ].
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procoagulant, generation of thrombin, or activation of the
tumor-associated proteinases [223]. In the presence of
VEGF, endothelial cells promote platelet activation [224].
Adhesion and aggregation of activated platelets are
accompanied by the release (mainly from  -granules)
of many potential angiogenesis regulators, such as:
VEGF-A [145], VEGF-C [225], bFGF [226], HGF
[227], insulin- like growth factor -1 and -2 [228,229],
epidermal growth factor [230], and platelet -derived
endothelial cell growth factor [231]. These sorts of
observations led Pinedo et al. [39] to hypothesize that
platelets may play an active and causative role in tumor
angiogenesis.
Platelets are the source of angiogenesis stimulators, but
also of angiogenesis inhibitors (Table 1) [39,40,232]. With
regard to the latter, platelet factor -4 (PF4) was the first
hemostatic protein demonstrated to be an inhibitor of
angiogenesis in vivo [40]. PF4 interacts with surface
heparin- like glycosaminoglycans on endothelial cells,
thereby blocking the binding sites for heparin -binding
endothelial growth factors [233–235]. PF4 also directly
inhibits bFGF dimerization and activity [236]. In addition,
PF4 inhibits the endothelial stimulatory activity of bFGF,
EGF, and VEGF121 by a mechanism independent of their
interactions with heparin sulfate proteoglycans [235]. This
is consistent with the observation that the analogue of PF4,
which lacks the heparin-binding capacity ( rPF4–241), is
also able to inhibit tumor angiogenesis [237]. This notion
was explored further by using various peptides derived
from PF4 [238]. Thus, the peptide derived from the C-
terminus of PF4 (residues 47–70) interferes with biological
functions of both bFGF and VEGF. It is puzzling that a
peptide derived from the central PF4 region (17–58),
containing a potential heparin -binding domain, apparently
does not interfere with endothelial cell responses to these
respective angiogenic ligands ( i.e., bFGF or VEGF).
However, this peptide inhibits heparin -dependent interac-
tions of these growth factors with their high-affinity
receptors, when these receptors are expressed ‘‘ectopi-
cally’’, i.e., in non-endothelial cells (e.g., CHO cells ) [239].
More recently, gene therapy approaches have been
developed to use modified PF-4 as an anti - tumor agent
[240].
TSP-1, a potent angiogenesis inhibitor, is also a
constituent of platelet  granules [241]. The central stalk
of TSP-1 interacts with CD36 receptor on the surface of
endothelial cells, resulting in angiogenesis inhibition
[241,242]. However, very high concentrations of TSP-1
can also stimulate angiogenesis via interaction with the
integrin-activating protein IAP/CD37 [241]. TSP-1 is also
involved in activation of the latent TGF-, thereby
triggering angiogenesis- regulating effects of this cytokine
[243]. Platelet -derived HGF can serve as another
example of this ‘‘one-mediator - two- functions’’ paradigm.
While essentially pro-angiogenic, HGF contains cryptic
anti -angiogenic subdomains in its  -chain [40,244]. Thus,
alternative splicing of the HGF mRNA can result in
expression of the first kringle domain inhibitor (NK1) or
first two kringle domain (NK2) inhibitor, both of which
suppress HGF- induced angiogenesis [233], as does the
recombinant HGF/NK4 variant [245].
Activated platelets stimulate endothelial cells to express
TF [246] and to form tubular networks in Matrigel, an effect
apparently independent of platelet aggregation or release
processes [232]. It was argued that adhesion of platelets to
endothelium via surface glycoproteins may be responsible
for this morphogenetic response [232]. Collectively, as with
other components of the hemostatic system, the role of
platelets in various aspects, stages, and forms of tumor
angiogenesis is complex and not fully amenable to simple
generalizations and predictions.
Summary
Processes regulating vascular expansion, homeostasis and
blood clotting intersect at many critical points. In the
context of cancer, this anatomical and functional mutual
interdependence is manifested by consistent co- incidence
of ‘‘cancer coagulopathy’’ and activation of tumor angio-
genesis. It is an open question to what extent one is the
cause or the consequence of the other. Nevertheless, the
explosion of findings implicating various hemostatic mech-
anisms in tumor growth and neovascularization is a
foundation of at least two novel therapeutic approaches
to treat cancer, namely: 1) derivation of hemostatic
proteins as angiogenesis inhibitors, and 2) using anti -
thrombotic pharmacotherapy (e.g., heparin or low-molec-
ular -weight heparin) to control blood vessel formation.
However, the great complexity of the hemostatic system
and the multitude of pro- and anti -angiogenic activities it
encodes (even within individual constituent proteins)
suggest that for each therapeutic action, a proper clinical
context should be precisely defined and validated. In this
regard, we have previously proposed that both the
molecular nature of ‘‘cancer coagulopathy’’ [63] and the
operating angiogenic mechanism [21] likely vary as a
function of tumor progression (angiogenesis progression )
as well as genetic and epigenetic variables characteristic of
each tumor type. We believe that it is important to consider
such tumor specific, heterogenous and evolving nature of
these respective host responses ( i.e., coagulopathy and
angiogenesis), while designing anti -angiogenic cancer
therapies based on interference with the hemostatic
system.
Table 1. Examples of Platelet -Derived Angiogenesis Stimulators and Inhibitors.
Platelet -Derived Angiogenesis Stimulators Platelet -Derived Angiogenesis Inhibitors
VEGF -A [150,225 ], VEGF -C [ 225 ], bFGF [226 ], HGF /SF [227 ], IGF -1 [ 228 ],
IGF -2 [ 229 ], EGF [230 ], PD -ECGF [249 ], Ang -1 [ 250 ]
PF -4 and PF -4 fragments [ 235,236,238 ], HGF domains NK1 and NK2
[ 245,251–253 ], TSP -1 [241,254,255 ]
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